Looking to the Future: A New Era of PAH Therapy

AMA/ANCC/ACPE Activity
Talking PAH is a webcast series that highlights the very latest clinical data in pulmonary arterial hypertension. Slides are developed and presented by leading PAH expert physicians and further reviewed and approved by the planning committee.
Over the past two decades, research has vastly improved the understanding of the pathophysiology, diagnosis, and treatment of pulmonary arterial hypertension (PAH). While no therapies have been approved to target new mechanisms of action in more than 15 years, multiple phase 2 and phase 3 clinical trials of novel therapies are underway. Further, management decisions regarding practical issues must also be addressed. Emerging research in accurate phenotyping of PH may also improve customization of therapies and prognostication as well as to increase the homogeneity of study cohorts in clinical trials. Improvements in the care of PAH patients depends on improving clinician awareness of the latest research into new diagnostic techniques, medications, and monitoring. This on-demand presentation is designed for the multi-disciplinary medical team and addresses the practical challenges of managing patients in the new era of PAH therapy.
FACULTY
Ronald Oudiz, MD, FACP, FACC, FCCP
Professor of Medicine
The David Geffen School of Medicine at UCLA
Chief, Division of Cardiology
Director, Pulmonary Hypertension Clinic
Harbor-UCLA Medical Center
Robert Schilz, DO, PhD
Director, Pulmonary Vascular Disease and Lung Transplantation
University Hospitals of Cleveland
Associate Professor of Medicine
Case School of Medicine
Review the activity at bit.ly/3XuA41I and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.
This activity is jointly provided by the University of Nebraska Medical Center, Duquesne University School of Pharmacy and Practice Point Communications
Supported by independent educational grants from United Therapeutics, a public benefit company; Bayer U.S.; and Actelion Pharmaceuticals U.S., Inc., A Janssen Pharmaceutical Company of Johnson & Johnson